Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
This story is reported by Intellia Therapeutics. Read what other outlets are saying below, then open the original report for full details.